FASLOMAX 250MG

Faslomax 250mg injection contains fulvestrant as its active ingredient. This antineoplastic medication is classified as an estrogen receptor antagonist. Estrogen, a female sex hormone, can sometimes contribute to the development of breast cancer. This medication is utilized on its own to treat postmenopausal women diagnosed with a specific type of breast cancer known as estrogen receptor-positive breast cancer, which may be locally advanced or have metastasized to other areas of the body. Additionally, it is prescribed in conjunction with other anti-cancer therapies for women with certain types of breast cancer referred to as hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, which is also locally advanced or has spread to other regions of the body.

You should not receive this injection if you are allergic to fulvestrant or any of the other components of this medication, if you are pregnant or breastfeeding, or if you have severe liver issues. Prior to starting treatment, it is essential to inform your healthcare provider if you have kidney or liver conditions, bone disorders, bleeding issues, or heart diseases. Faslomax 250mg injection is not intended for use in children and adolescents under the age of 18. Notify your doctor if you experience any allergic reactions, such as swelling of the face, lips, tongue, or throat, following the administration of this injection.

Common side effects associated with Faslomax 250mg injection include pain or inflammation at the injection site, abnormal liver enzyme levels, nausea, headaches, coughing, weakness or fatigue, joint and muscle discomfort, hot flashes, hair loss, and skin rashes. Your physician may recommend specific blood tests while you are receiving this injection. This medication may elevate your risk of bleeding and liver failure. Women of reproductive age should employ effective contraception during treatment with this injection and for two years following the final dose.